Date: 2012-11-05
Type of information: Licensing agreement
Compound: transiently transfected CAP-TTM cells for cell based assay and protein production applications
Company: CEVEC Pharmaceuticals (Germany) CCS Cell Culture Service (Germany)
Therapeutic area:
Type agreement: licensing
Action mechanism: The transient CAP-TTM protein production technology is based on CAP® cells, an immortalized cell line for stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
Disease:
Details: CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and CCS Cell Culture Service , a contract research organization based in Hamburg, Germany, have announced the signing of a strategic license agreement. The license will enable CCS to offer its customers transiently transfected CAP-TTM cells for cell based assay and protein production applications.
The collaboration combines CEVEC\'s proprietary CAP-TTM expression system with CCS\' expertise to produce and process bulk quantities of transiently transfected cells for drug discovery research in pharmaceutical companies worldwide.
Financial terms:
Latest news:
